Europe’s drug regulator said it is reviewing reports of rare blood clots in four people who received Johnson & Johnson’s COVID-19 vaccine and has expanded its probe into AstraZeneca’s shot to include reports of a bleeding condition.
Of the four serious cases of clotting and low platelets, three occurred in the United States during the rollout of J&J’s vaccine from its Janssen unit, the European Medicines Agency (EMA) said on Friday, adding that one person had died and that one case was reported in a clinical trial.
It was the first news of EMA’s probe of the J&J vaccine, while AstraZeneca’s coronavirus vaccine has been dogged for weeks over possible links to rare blood clots in the brain and abdomen, which the EMA has confirmed.
U.S.-based J&J said that it was aware of the reports of blood clots possibly related to its COVID-19 vaccine and others, and is working with regulators to assess the data and provide relevant information.
Source: Reuters